{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:42:06Z","timestamp":1790635326097,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine whether reproxalap, a novel reactive aldehyde species (RASP) inhibitor, is safe and effective for the treatment of the signs and symptoms of dry eye disease (DED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In a randomized double-masked parallel-group Phase 2a trial of 3 topical ocular reproxalap formulations (0.1% ophthalmic solution, 0.5% ophthalmic solution, and 0.5% lipid ophthalmic solution), 51 patients with DED were randomly assigned 1:1:1 at a single US site. Eyes were treated bilaterally 4 times daily for 28 days, and standard DED signs and symptoms were assessed at baseline and after 7 and 28 days of dosing. Tear RASP levels were assessed at baseline and at day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The effect of treatment on DED signs and symptoms was similar across the treatment arms, and pooled data from the 28-day treatment period demonstrated significant improvement from baseline in Symptom Assessment in Dry Eye Disease score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.003), Ocular Discomfort Scale score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), Ocular Discomfort Score and 4-Symptom Questionnaire overall score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0004), Schirmer's test (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.008), tear osmolarity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.003), and lissamine green total staining score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.002). Improvements in DED symptoms were evident within 1 week of therapy, and effect sizes generally approached or exceeded 0.5. No significant changes in safety measures were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results suggest that the novel RASP inhibitor reproxalap has the potential to mitigate the signs and symptoms of DED, and may represent a new, rapidly and broadly active treatment approach for DED (NCT03162783).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0087","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T17:12:21Z","timestamp":1610730741000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease"],"prefix":"10.1177","volume":"37","author":[{"given":"David","family":"Clark","sequence":"first","affiliation":[{"name":"Aldeyra Therapeutics, Lexington, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Virginia Eye Consultants, Norfolk, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Brady","sequence":"additional","affiliation":[{"name":"Aldeyra Therapeutics, Lexington, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.06.033"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0919-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.10.001"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S137580"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.10.011"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0646-5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2015.11.002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/NHH.0000000000000652"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.186"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep46453"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111752"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.09.010"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2012.05.005"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0517-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550310003782"},{"key":"e_1_3_3_18_2","first-page":"997","article-title":"The role of conjunctival epithelial cell xanthine oxidoreductase\/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjogren's syndrome","volume":"22","author":"Cejkova J.","year":"2007","unstructured":"Cejkova J., , Ardan T., , Jirsova K., et al. The role of conjunctival epithelial cell xanthine oxidoreductase\/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjogren's syndrome. Histol. Histopathol. 22:997\u20131003, 2007.","journal-title":"Histol. Histopathol"},{"key":"e_1_3_3_19_2","first-page":"443","article-title":"Investigation of oxidative stress in pterygium tissue","volume":"17","author":"Balci M.","year":"2011","unstructured":"Balci M., , Sahin S., , Mutlu F.M., , Yagci R., , Karanci P., , and Yildiz M. Investigation of oxidative stress in pterygium tissue. Mol. Vis. 17:443\u2013447, 2011.","journal-title":"Mol. Vis"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.830753"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-1030-3"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081783"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.161679"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.06.002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1999.0234"},{"key":"e_1_3_3_26_2","first-page":"2465","article-title":"Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease","volume":"16","author":"Wakamatsu T.H.","year":"2010","unstructured":"Wakamatsu T.H., , Dogru M., , Ayako I., et al. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol. Vis. 16:2465\u20132475, 2010.","journal-title":"Mol. Vis"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00164671"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1098707"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2012.07.010"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2011.03.003"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Cullen V. Mechanic J. Welihinda A. Young S. Amento E. and Brady T.C. The small molecule aldehyde trap NS2 exhibits potent anti-inflammatory activity in three murine models of inflammation. Poster presented at: American Academy of Asthma Allergy and Immunology Annual Meeting; February 20-24 2015; Houston TX.","DOI":"10.1016\/j.jaci.2014.12.1884"},{"key":"e_1_3_3_32_2","unstructured":"Cullen V. Young S.L. Parker G.L. Lyng G. Brady T.C. and Sonis S.T. Administration of the small molecule aldehyde trap NS2 in a hamster model of radiation-induced oral mucositis. Poster presented at: Supportive Care in Cancer Annual Meeting; June 25-27 2015; Copenhagen Denmark."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44688"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S38732"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S39356"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70053-8"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.20982\/tqmp.01.1.p042"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:13Z","timestamp":1777646653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5,1]]}},"alternative-id":["10.1089\/jop.2020.0087"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0087","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}